EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Do-it-yourself game plans

Stage 2: How do you screen GLP-1 supply-route eligibility?

Dose Diligence research deskSection 02 · Page 4 of 17Last updated 17 Nov 2026

Assess the actual arrangement, not the supplier's category label. Use one record for each product, preparation, facility, intended use and destination-state combination.

What regulatory developments should buyers account for?

The following are decision-relevant findings from the sources reviewed:

  • FDA determined the tirzepatide injection shortage resolved on December 19, 2024, after re-evaluation, and the semaglutide injection shortage resolved on February 21, 2025. Its April 1, 2026 update states that neither appears on its shortage list or 503B bulks list. FDA policy update.
  • The Fifth Circuit affirmed the district-court judgments in the shortage litigation on August 27, 2026; the available semaglutide opinion was revised September 1, 2026. These opinions are not a substitute for checking subsequent orders affecting a proposed transaction. Tirzepatide opinion; semaglutide opinion.
  • FDA announced a proposal, not a final determination, on April 30, 2026, not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. The comment deadline was subsequently extended to July 30, 2026. This research did not locate a later final determination; do not describe the proposal as a final rule. FDA announcement; extension notice.

These developments make shortage-era supplier materials unsuitable as stand-alone procurement evidence. Recheck the FDA shortage database, applicable policies and relevant court orders immediately before commitment. (fda.gov)

How do 503A, 503B and approved-product routes differ?

Proposed routeWhat the buyer should establishWhat not to assume
Approved medicine purchased for clinic stockPurchasing eligibility; authorised supply chain; permitted clinic handling and intended use; exact presentationA patient cash-price offer is a wholesale quote
Approved medicine dispensed to a patientDispensing entity; destination permissions; prescription workflow; payment and programme eligibilityAn access platform is necessarily the dispensing pharmacy
Patient-specific preparation under 503AApplicable prescription requirement and all other statutory conditions, including restrictions on essentially copying commercially available productsA prescription alone authorises the preparation
Proposed outsourcing supply under 503BFacility registration, product-specific conditions, bulk-substance eligibility where relevant, copying restrictions and applicable state requirementsRegistration grants permission to supply any GLP-1 preparation

The compounding distinctions above follow FDA's 503A prescription guidance, 503A essentially-copy guidance, 503B bulk-substance information and outsourcing-facility registration explanation.

Can a clinic buy compounded GLP-1 for office use?

Do not treat 503A patient-specific dispensing as a general office-stock route. FDA's prescription guidance distinguishes supply for an identified patient from stock held for unspecified future patients. Section 503B can accommodate arrangements without individual prescriptions, but the proposed drug must still satisfy the pathway's other conditions. 503A guidance; 503B explanation.

Ask counsel to distinguish patient-labelled medication delivered to a practice for that patient's treatment from unrestricted office inventory. Have counsel separately assess any proposed onward distribution, dispensing or administration by the clinic.

Does adding B12 make compounded semaglutide permissible?

Not automatically. FDA's April 2026 explanation specifically discusses semaglutide combined with vitamin B12 and circumstances in which the product may still be essentially a copy. The 503A guidance also says a lower price does not establish the required significant difference. FDA policy explanation; 503A guidance.

Do not ask prescribers to sign a supplier's blanket clinical-difference statement simply to unlock a commercial offer. Refer any patient-specific rationale to clinical leadership and counsel.

What should the legal-review brief contain?

Use this template:

Proposed transaction: Who supplies what, to whom, from which facility, for which patients or clinic use?
Product identity: Approved product and presentation, or complete proposed compounded formulation.
Jurisdictions: Facility state, clinic state and patient destination states.
Supplier's asserted basis: Written explanation with cited authority and dates.
Independent evidence: Current primary sources and licence records.
Questions: Which conditions apply, which are met, and which remain unresolved?
Decision: Proceed, proceed subject to documented conditions, or stop.
Reassessment triggers: Product, facility, state, ownership, law, enforcement or court-order change.

Stage 2 exit document: a dated assessment signed off by the appropriate legal and clinical decision-makers—not an automated legal score.

Explore the table row by row

A working view of the research

Approved medicine purchased for clinic stock

What the buyer should establish
Purchasing eligibility; authorised supply chain; permitted clinic handling and intended use; exact presentation
What not to assume
A patient cash-price offer is a wholesale quote

Answers stay in this session unless you choose to save. No account needed.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. ca5.uscourts.gov · Source 2 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
  3. ca5.uscourts.gov · Source 3 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  4. fda.gov · Source 4 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  5. public-inspection.federalregister.gov · Source 5 ↗https://public-inspection.federalregister.gov/2026-12937.pdf
  6. accessdata.fda.gov · Source 6 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  7. fda.gov · Source 7 ↗https://www.fda.gov/media/97347/download
  8. fda.gov · Source 8 ↗https://www.fda.gov/media/98973/download
  9. fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
Section sources →